UCMSCC

Small molecule

FFuzhou General Hospital

UCMSCC is one of 3 small molecule programs targeting Nervous System Injury. It is currently in development.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Nervous System InjuryActive, not recruiting

Nervous System InjuryPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

3 competitors in Nervous System Injury

#DrugCompanyPhaseTrials

Triapine

VVion Pharmaceuticals

Phase 2

—2

MS Contin

HHikma Pharmaceuticals LLC

Preclinical

—3

UCMSCC

FFuzhou General Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Nervous System Injury1 trial

Mesenchymal Stem Cells in Central Nervous System injury2017

Unknown status·FFuzhou General Hospital·Phase 1/2·NCT03291366·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for UCMSCC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — UCMSCC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for UCMSCC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Fuzhou General Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Company: FFuzhou General Hospital

UCMSCC

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Nervous System Injury1 trial

References

Drug Info

Quick Facts

Related News